Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pegenzileukin - Sanofi

Drug Profile

Pegenzileukin - Sanofi

Alternative Names: IBI-127; Non alpha IL-2 - Sanofi; Non alpha synthorin of IL-2 - Sanofi; SAR-444245; THOR-707

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Synthorx
  • Developer Merck Sharp & Dohme; Sanofi
  • Class Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins; Recombinant proteins
  • Mechanism of Action Interleukin-2 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II B-cell lymphoma; Gastrointestinal cancer; Hodgkin's disease; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Squamous cell cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 25 Jul 2023 Sanofi withdraws phase-II trial in Squamous cell cancer (Combination therapy, Neoadjuvant therapy) in USA (IV) prior to enrolment due to principal investigator request (NCT05535023)
  • 08 Jun 2023 Pharmacodynamics data from preclinical studies in Solid tumours presented at the 28th Congress of the European Haematology Association (EHA-2023)
  • 14 Apr 2023 Pharmacodynamics data from a phase I/II trial in Solid tumours at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top